TheEdgeResearch
Home / Stocks / ENZY.ST

Enzymatica AB (publ) (ENZY.ST)

STO Healthcare Drug Manufacturers - Specialty & Generic
$1.67 ▼ -1.48%
Market Cap
$404.2M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.40
52-Wk Range
1.55-3.4
CEO
Sana Alajmovic
Country
SE
Currency
SEK

Enzymatica AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $1.67, down 1.48% on the session, giving a market capitalisation of $404.2M. Its beta of -0.40 implies it has historically moved less than the broad market.

Company profile
Exchange
Stockholm Stock Exchange
Employees
18
IPO date
2011-06-14
Headquarters
Lund, SN, SE
About Enzymatica AB (publ)

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.

Comparable companies

Enzymatica AB (publ) is most often compared with the following Healthcare names:

ACE.STALZCUR.STCLBIO.STERMA.STFLUO.STIMMU.STMAGLE.STMOB.STNANEXA.STXINT.ST
More research on ENZY.ST
ENZY.ST technical analysis ENZY.ST TheEdge Score Compare against peers
Open full interactive analysis & DCF →